⌕
Aurinia Pharmaceuticals · AUPH · Nasdaq
Tenet 82 · Strong
Compare
$15.40−0.52%At closeTenet 82 · Strong
$15.40−0.08 (−0.52%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Aurinia Pharmaceuticals (AUPH) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~57.8%/yr (FY21→FY25), net margin 101.5%; free cash flow runs at 47% of net income. Check the accrual gap. Worth your attention in FY25: Share count (+7.2%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲20.4%
283.1
FY21→FY25CAGR +57.8%/yr
Net income ($M)▲4893.1%
287.2
one-off year: see footnoteCAGR —
Free cash flow ($M)▲207.0%
135.4
FY21→FY25CAGR —
Diluted EPS▲5075.0%
2.07
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+7.2%

129.4mn → 138.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$252.0K

steady at 0.1% of revenue (−10.3% YoY).

Returns vs FCF
72%

$98.2M returned vs $135.4M of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)283.1Revenue−32.7COGS250.4Gross profit−32.5R&D−101.8SG&A104.9Op income182.3Tax & other287.2Net income

101¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1108355280%sector median net margin ~3%FY21FY25

Net margin 101.5% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
321,738.0283,055.0235,133.0175,513.0134,030.045,605.0▲20.4%+57.8%
Cost of revenue
30,165.032,665.028,248.014,148.05,664.01,091.0▲15.6%+133.9%
Gross profit
291,573.0250,390.0206,885.0161,365.0—A—A▲21.0%+24.6%
Research & development
48,028.032,505.020,785.049,641.044,988.051,139.0▲56.4%−10.7%
Selling, general & admin
99,476.0101,794.0172,028.0195,036.0196,371.0173,536.0▼40.8%−12.5%
Total operating expenses
135,208.0145,476.0211,572.0253,056.0239,836.0225,249.0▼31.2%−10.4%
Operating incomefeeds ROC rank
156,365.0104,914.0−4,687.0−91,691.0−111,470.0−180,735.0——
Other income, net
10,751.09,243.012,135.014,222.05,118.0529.0——
Pretax income
167,116.0114,157.07,448.0−77,469.0−106,352.0−180,206.0▲1432.7%—
Income tax
−147,150.0−173,045.01,696.0551.01,828.0760.0——
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
314,266.0287,202.05,752.0−78,020.0−108,180.0−180,966.0▲4893.1%—
Per share
Diluted EPSbuyback-sensitive
2.282.070.04−0.54−0.76−1.40▲5075.0%—
Diluted shares (mn)
135.17138.70146.19143.24141.91129.37▼5.1%+1.8%
Margins
Gross margin86th pct in Healthcare
90.6%88.5%88.0%91.9%—A—A▲0.5pp−3.5pp
Operating margin
48.6%37.1%−2.0%−52.2%−83.2%−396.3%▲39.1pp+433.4pp
Net margin
97.7%101.5%2.4%−44.5%−80.7%−396.8%▲99.0pp+498.3pp
† TTM = trailing four quarters through 2026-09-30.FY24 effective tax rate was 23% vs a −1% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was −152% vs a −1% norm for this window, likely a one-time item; see the filing.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.
FY16 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Aurinia Pharmaceuticals' revenue last fiscal year?

Aurinia Pharmaceuticals reported revenue of $283.1M in fiscal 2025, up 20.4% from fiscal 2024.

What was Aurinia Pharmaceuticals' net income?

Aurinia Pharmaceuticals reported net income of $287.2M in fiscal 2025, a net margin of 101.5%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.